Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.55 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | DNM1L | O00429 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17504066 | 1.00 | SLC6A3 (0.55) | SLC6A3DRD2HTR2ADNM1LHPGDS | |
| SCHEMBL17504071 | 0.85 | SLC6A3 (0.39) | SLC6A3 | |
| SCHEMBL21462404 | 0.78 | SLC6A3 (0.35) | SLC6A3NOS1 | |
| SCHEMBL17504082 | 0.78 | SLC6A3 (0.54) | SLC6A3 | |
| SCHEMBL18985021 | 0.75 | SLC6A3 (0.34) | SLC6A3 | |
| SCHEMBL21462480 | 0.74 | SLC6A3 (0.34) | SLC6A3 | |
| SCHEMBL21462305 | 0.74 | SLC6A3 (0.34) | SLC6A3 | |
| SCHEMBL17504104 | 0.74 | SLC6A3 (0.34) | SLC6A3 | |
| SCHEMBL17504070 | 0.74 | SLC6A3 (0.34) | SLC6A3 | |
| SCHEMBL17504089 | 0.73 | SLC6A3 (0.62) | SLC6A3DRD2HTR2ADNM1LHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210380545-A1 | (S)-ENANTIOMERIC FORM OF A HETEROCYCLIC COMPOUND HAVING MOTIVATION IMPROVING AND/OR REFERENCE MEMORY ENHANCING ACTIVITY | RED BULL GMBH (AT) | 2021-12-09 | — | — | US | claimed |
| US-20210380545-A1 | (S)-ENANTIOMERIC FORM OF A HETEROCYCLIC COMPOUND HAVING MOTIVATION IMPROVING AND/OR REFERENCE MEMORY ENHANCING ACTIVITY | RED BULL GMBH (AT) | 2021-12-09 | — | — | US | disclosed |
| WO-2019197670-A1 | (S)-ENANTIOMERIC FORM OF A HETEROCYCLIC COMPOUND HAVING MOTIVATION IMPROVING AND/OR REFERENCE MEMORY ENHANCING ACTIVITY | RED BULL GMBH (AT) | 2019-10-17 | — | — | WO | disclosed |
| EP-3553053-A1 | (S)-ENANTIOMERIC FORM OF A HETEROCYCLIC COMPOUND HAVING MOTIVATION IMPROVING AND/OR REFERENCE MEMORY ENHANCING ACTIVITY | Red Bull GmbH (AT) | 2019-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380545-A1 | (S)-ENANTIOMERIC FORM OF A HETEROCYCLIC COMPOUND HAVING MOTIVATION IMPROVING AND/OR REFERENCE MEMORY ENHANCING ACTIVITY | TFEB, TAAR1, RABGGTB | SLC6A3 444/4885DRD2 36/4885HTR2A 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.